Literature DB >> 22542126

Histologic grading of urothelial carcinoma: a reappraisal.

Liang Cheng1, Gregory T MacLennan, Antonio Lopez-Beltran.   

Abstract

A uniform grading system for bladder cancer will allow for valid comparison of treatment results among different centers. The introduction of the World Health Organization (2004)/International Society of Urological Pathology classification is a welcome step toward standardization of treatment and follow-up regimens. The greatest source of controversy with the World Health Organization (2004)/International Society of Urological Pathology classification system centers on the diagnosis of papillary urothelial neoplasm of low malignant potential. Some feel that papillary urothelial neoplasm of low malignant potential terminology increases the complexity of histologic grading and does not accurately reflect biologic potential. Papillary urothelial neoplasm of low malignant potential is a low-grade papillary urothelial neoplasm with a substantial incidence of recurrence and progression. In the distinction of papillary urothelial neoplasm of low malignant potential from noninvasive low-grade papillary urothelial carcinoma, there is considerable interobserver variability. For these reasons, some investigators believe that papillary urothelial neoplasm of low malignant potential is, in essence, an entity that was previously designated grade 1 urothelial carcinoma in the World Health Organization 1973 grading system. In addition, treatment and follow-up regimens for patients with papillary urothelial neoplasm of low malignant potential do not typically differ from those prescribed for low-grade, noninvasive urothelial carcinoma, further minimizing the clinical need for the papillary urothelial neoplasm of low malignant potential distinction to be made. We propose abandonment of the terminology "papillary urothelial neoplasm of low malignant potential" in bladder tumor classification. Full-genome searches for prognostic and predictive molecular gene expression signatures as cancer markers have shown significant promise. Recent advances in the molecular grading of these tumors may eventually supplant traditional morphologic grading systems, allowing a more precise and objective assessment of the tumors' biologic potentials.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22542126     DOI: 10.1016/j.humpath.2012.01.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  SIU-ICUD on bladder cancer: pathology.

Authors:  Eva Compérat; Marek Babjuk; Ferran Algaba; Mahul Amin; Fadi Brimo; David Grignon; Donna Hansel; Ondra Hes; Bernard Malavaud; Victor Reuter; Theo van der Kwast
Journal:  World J Urol       Date:  2018-09-14       Impact factor: 4.226

2.  [Non-invasive and invasive urothelial tumours: special challenges in uropathological diagnostics].

Authors:  N T Gaisa; K Lindemann-Docter
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

3.  Phase distribution analysis of tissues based on the off-axis digital holographic hybrid reconstruction algorithm.

Authors:  Yunyi Lin; Liang Dong; Haige Chen; Sujuan Huang
Journal:  Biomed Opt Express       Date:  2017-12-04       Impact factor: 3.732

4.  Noninvasive low-grade papillary urothelial carcinoma with degenerative nuclear atypia: a grading pitfall.

Authors:  Andres Matoso; Vamsi Parimi; Jonathan I Epstein
Journal:  Hum Pathol       Date:  2021-04-19       Impact factor: 3.526

5.  Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.

Authors:  Jay P Maxwell; Cheng Wang; Nicholas Wiebe; Asli Yilmaz; Kiril Trpkov
Journal:  Diagn Pathol       Date:  2015-03-13       Impact factor: 2.644

6.  Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder.

Authors:  Ok Målfrid Mangrud; Rune Waalen; Einar Gudlaugsson; Ingvild Dalen; Ilker Tasdemir; Emiel A M Janssen; Jan P A Baak
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

7.  Genetic variations rs11892031 and rs401681 are associated with bladder cancer risk in a Chinese population.

Authors:  Yu Zhang; Yan Sun; Tao Chen; Hailong Hu; Wanqin Xie; Zhihui Qiao; Na Ding; Linguo Xie; Sheng Li; Wenlong Wang; Chen Xing; Yihan Wang; Yunkai Qie; Changli Wu
Journal:  Int J Mol Sci       Date:  2014-10-24       Impact factor: 5.923

8.  Level of mitoses in non-muscle invasive papillary urothelial carcinomas (pTa and pT1) at initial bladder biopsy is a simple and powerful predictor of clinical outcome: a multi-center study in South Korea.

Authors:  Ji Eun Kwon; Nam Hoon Cho; Yeong-Jin Choi; So Dug Lim; Yong Mee Cho; Sun Young Jun; Sanghui Park; Young A Kim; Sung-Sun Kim; Mi Sun Choe; Jung-Dong Lee; Dae Yong Kang; Jae Y Ro; Hyun-Jung Kim
Journal:  Diagn Pathol       Date:  2017-07-24       Impact factor: 2.644

9.  Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma.

Authors:  Mohamed Reda El Ochi; Mohamed Oukabli; Elarbi Bouaiti; Hafsa Chahdi; Adil Boudhas; Mohamed Allaoui; Ahmed Ameur; Mohamed Abbar; Abderrahmane Al Bouzidi
Journal:  BMC Clin Pathol       Date:  2017-04-04

Review 10.  Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer.

Authors:  Julieti Huch Buss; Karine Rech Begnini; Camila Bonemann Bender; Adriana R Pohlmann; Silvia S Guterres; Tiago Collares; Fabiana Kömmling Seixas
Journal:  Front Pharmacol       Date:  2018-01-12       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.